Results 31 to 40 of about 10,738 (252)

Red-Brown Urine Discolouration in Two Patients Taking Mesalamine [PDF]

, 2016
A 38-year-old male and a 36-year-old female experienced red-brown urine discolouration after 2 and 3 days, respectively, during the use of mesalamine for inflammatory bowel disease.
Florence van Hunsel, Tim Smeets
core   +1 more source

Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications

Canadian Journal of Gastroenterology and Hepatology, 2016
Background. Ulcerative proctitis (UP) is typically treated initially with oral 5-aminosalicylate (“5-ASA”), mesalamine suppository, or mesalamine enema (“UP Rx”). Little is known about their effectiveness in practice. Methods. Using a US health insurance
James M. Richter, Nabeela K. Arshi, Gerry Oster   +2 more
doaj   +1 more source

Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels [PDF]

, 2015
INTRODUCTION: Oral formulations of 5-aminosalicylic acid (5-ASA) for treatment of ulcerative colitis have been developed to minimize absorption prior to the drug reaching the colon.
Adeyinka Abinusawa, Srini Tenjarla
core   +1 more source

Design and Characterization of Mesalamine Loaded Nanoparticles for Controlled Delivery System [PDF]

Nanomedicine Research Journal, 2016
Objective(s): Nanoparticles (NPs) are known for their specific accumulation in the inflamed tissues of the colon and thus allow a selective delivery to the site of inflammation with minimum adverse effects.
Simin Seifirad, Hasan Karami, Shadab Shahsavari, Farzad Mirabasi, Farid Dorkoosh   +4 more
doaj   +1 more source

One of the 5-aminosalicylates drug, mesalamine as a drug repurposing lead against breast cancer

Bulletin of the National Research Centre, 2022
Background Breast cancer is the world's second leading cause of death in women. The problem of chemoresistance in breast cancer is proving to be a challenge for researchers and several oncologists all around the world.
Dayanand Swami, Shafina Siddiqui, Urwashi Kumar, Shine Devarajan, Jyotirmoi Aich   +4 more
doaj   +1 more source

PAK1 modulates a PPARγ/NF-κB cascade in intestinal inflammation [PDF]

, 2015
P21-activated kinases (PAKs) are multifunctional effectors of Rho GTPases with both kinase and scaffolding activity. Here, we investigated the effects of inflammation on PAK1 signaling and its role in colitis-driven carcinogenesis.
Alastair Watson, Campregher, Carter, Chen, Christoph Gasche, D. Mark Pritchard, Dammann, Dammann, Dubuquoy, Felix Harpain, Frost, Fu, Greten, Hauser, Hoesel, Hou, Jagadeeshan, Jonathan M. Williams, Kant, Karin, Khare, Khare, Khare, Kim, Kumar, Kyle Dammann, Lee, Michaela Lang, Myant, Neumann, Neurath, Nicolas Granofszky, Park, Parrini, Puls, Radu, Rayko Evstatiev, Roig, Rousseaux, Rousseaux, Rubin, Sakurai, Sato, Schwitalla, Stockton, Suzawa, Thierry Claudel, Tontonoz, Vadlamudi, Velayos, Vineeta Khare, Wang, Wang, Williams, Wojciak-Stothard, Yang, Yin, Yu, Zenke, Zhou, Zhu   +60 more
core   +1 more source

The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.

PLoS ONE, 2014
UnlabelledThe anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. The effect of mesalamine in HIV-infected individuals, who exhibit abnormal mucosal immune activation and ...
Ma Somsouk, Richard M Dunham, Michelle Cohen, Rebecca Albright, Mohamed Abdel-Mohsen, Teri Liegler, Jeffrey Lifson, Michael Piatak, Robert Gorelick, Yong Huang, Yuaner Wu, Priscilla Y Hsue, Jeffrey N Martin, Steven G Deeks, Joseph M McCune, Peter W Hunt   +15 more
doaj   +1 more source

Probiotics in the treatment of diverticular disease. A systematic review [PDF]

, 2016
BACKGROUND AND AIMS: Diverticular disease is a common gastrointestinal condition. Low-grade inflammation and altered intestinal microbiota have been identified as factors contributing to abdominal symptoms.
ANNIBALE, Bruno, Bellisario, Cristina, ESPOSITO, GIANLUCA, Hassan, Cesare, LAHNER, EDITH, Zullo, Angelo   +5 more
core   +1 more source

Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease [PDF]

Intestinal Research, 2020
Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis.
Ajit Sood, Vineet Ahuja, Vandana Midha, Saroj Kant Sinha, C. Ganesh Pai, Saurabh Kedia, Varun Mehta, Sawan Bopanna, Philip Abraham, Rupa Banerjee, Shobna Bhatia, Karmabir Chakravartty, Sunil Dadhich, Devendra Desai, Manisha Dwivedi, Bhabhadev Goswami, Kirandeep Kaur, Rajeev Khosla, Ajay Kumar, Ramit Mahajan, S. P. Misra, Kiran Peddi, Shivaram Prasad Singh, Arshdeep Singh   +23 more
doaj   +1 more source

Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of study was to generate quantitative data on the abundance of drug‐metabolizing enzymes and transporters (DMETs) in inflamed and non‐inflamed Crohn's disease (CD) ileum and colon, for incorporation into physiologically based pharmacokinetic (PBPK) models, enabling prediction of oral drugs' pharmacokinetics (PK) perturbation in CD patients.
Sarah Alrubia, Brahim Achour, Zubida M. Al‐Majdoub, Amin Rostami‐Hodjegan, Jill Barber   +4 more
wiley   +1 more source